References
- Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteraemia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004; 38: 448–51
- Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38: 521–8
- Howden BP. Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA). Intern Med J 2005; 35 Suppl 2: 136–40
- Kim HB, Lee YS, Kim BS, Cha JO, Kwon SU, Lee HJ, et al. Prevalence and clinical implications of Staphylococcus aureus with a vancomycin MIC of 4 microg/ml in Korea. Microb Drug Resist 2006; 12: 33–8
- NCCLS. Performance Standards for Antimicrobial Susceptibility Testing: 14th Informational Supplements. NCaS document M 100-S14, Wayne, PA: NCaS. 2004.
- Naffa RG, Bdour SM, Migdadi HM, Shehabi AA. Enterotoxicity and genetic variation among clinical Staphylococcus aureus isolates in Jordan. J Med Microbiol 2006; 55: 183–7
- Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670–3
- CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
- Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006; 42 Suppl 1: 13–24
- Fowler VG, Jr, Sakoulas G, McIntyre LM, Meka VG, Arbeit RD, Cabell CH, et al. Persistent bacteraemia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis 2004; 190: 1140–9
- Khatib R, Johnson LB, Fakih MG, Riederer K, Khosrovaneh A, Shamse Tabriz M, et al. Persistence in Staphylococcus aureus bacteraemia: incidence, characteristics of patients and outcome. Scand J Infect Dis 2006; 38: 7–14
- Green MS, Prystowsky JH, Cohen SR, Cohen JI, Lebwohl MG. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol 1996; 34: 911–4
- Haraga I, Nomura S, Fukamachi S, Ohjimi H, Hanaki H, Hiramatsu K, et al. Emergence of vancomycin resistance during therapy against methicillin-resistant Staphylococcus aureus in a burn patient: importance of low-level resistance to vancomycin. Int J Infect Dis 2002; 6: 302–8
- Aritaka N, Hanaki H, Cui L, Hiramatsu K. Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin. Antimicrob Agents Chemother 2001; 45: 1292–4